



ASX: EIQ RELEASE

7 March 2025

Investor Webinar Presentation

Sydney: AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) is pleased to provide the attached presentation, which will be used during the Company’s upcoming webinar scheduled for 11:00am AEDT on Thursday, 13 March 2025.

Anyone wishing to attend the webinar must register using the below link:

https://us02web.zoom.us/webinar/register/WN_FwV0VdnITaCFsHZeRq4VBg#/registration

During the webinar, Chief Executive Officer Mr Dustin Haines will provide an update on progress around the Company’s US commercialisation strategy for EchoSolv AS over the first two months of 2025, along with a near-term outlook summary on Echo IQ’s clinical development pipeline.

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ


Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.



Webinar Presentation
March 2025

ASX: EIQ

OTC: ECHQ.F






Andrew Grover
Executive Chairman

Mr Grover brings 25 years' experience in growing successful businesses across a diverse range of industries. As a founder and investor in numerous innovative companies, his businesses have been featured in BRW Fast 100 and Deloitte's Fast 50 over several years.



Dustin Haines
Chief Executive Officer

Mr Haines brings 25 years' experience in leading global businesses in pharmaceuticals, biotechnology, and medical devices. Most recently, Mr Haines was head of Asia, Middle East, Turkey, and Russia for Gilead Sciences where he managed over \$1.2B in revenue. As a leader, Mr. Haines has launched innovative technologies globally with extensive experience in regulatory approvals, reimbursement, commercialization, and scaling businesses.



NEXT SCIENCE®

Board of Directors



Steven Formica
Board Member

Steven Formica brings to the company significant business management and development experience. He has led a number of privately held business ventures across multiple industry sectors. Mr Formica is currently the non-executive chairman of ASX-listed Ragnar Metals (ASX:RAG), non-executive chairman of ASX-listed Albion Resources Ltd (ASX: ALB), non-executive chairman of ASX-listed Kaiser Reef Limited (ASX: KAU), non-executive director of ASX-listed Bindi Metals (ASX:BIM), non-executive director of ASX-Listed Great Northern Minerals Limited (ASX: GNM), and a successful investor in a number of ASX listed entities.



Steve Picton
Board Member

Steve Picton is an experienced Board Director and business leader. As CEO of mobile virtual network operator goTalk Limited, he increased revenues to more than \$100M. Mr Picton holds a Bachelor of Science in technology and a Master of Science (Business) from London Business School and is both a Chartered Engineer and a Member of The Institute of Company Directors. He is also a Sloan Fellow which was awarded to him in 1993 by the Sloan Foundation as part of the joint MIT, Stanford and LBS programme. Mr Picton is currently the non-executive chairman of ASX-listed FlexiRoam Ltd (ASX: FRX).



Ken Nelson
Board Member

Ken Nelson is a leading US-based medical technology and healthcare executive with 20+ years' industry experience. During his career he has been pivotal in leading successful commercialization efforts with multiple cardiac-focused digital health companies including remote cardiac and diagnostics monitoring business, BioTelemetry, wearable device company, iRhythm and ambulatory ECG solutions monitoring group, Bardy Diagnostics. Currently, he serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator (www.medtechinnovator.org), the largest medical technology and digital health startup accelerator globally.



Jessamyn Lyons
Company Secretary

Jessamyn Lyons is a Chartered Secretary, a Fellow of the Governance Institute of Australia and holds a Bachelor of Commerce from the University of Western Australia with majors in Investment Finance, Corporate Finance and Marketing. Jess is a highly experienced Company Secretary and formerly she held positions with Macquarie Bank, UBS (London) and Patersons Securities (now Canaccord Genuity Ltd).

Management team



Deon Strydom
Chief Operating Officer

Deon Strydom is an experienced executive with over 15 years' experience in the pharmaceutical and biotech industries. Working within multinational, start-up and early-stage companies, he is passionate about supporting organisations wishing to implement scalable systems and achieve accelerated growth.



Sam Dribin
Chief Technology Officer

Sam Dribin's specialties include Biotech software development, AI, DevOps, and Cloud Architecture, FDA, ISO-13485, and HIPAA compliant software, feasibility assessment, agile and extreme methodologies.

He has expertise in the technical issues facing healthcare, biotech companies and laboratories.



Don Fowler
President, Echo IQ US

Leveraging experiences as a CEO, Chairman and Director, VP Global Sales and Marketing, and Consultant, Don Fowler is a trusted business advisor and partner.

Mr Fowler is skilled at distilling complex challenges and projects into simple, executable strategies that create enterprise value and scale top line revenue.



Dane Brescacin
VP Regulatory Affairs

Dane Brescacin brings 15 years of experience in a regulatory environment, working across the biotechnology and medical technology industries. He has extensive experience in medical device 510k regulatory process.



NEXT SCIENCE®



Specialist Advisors & Scientific Advisory Board

Echo IQ has unparalleled scientific backing:

- Globally recognized experts in cardiovascular medicine, echocardiography, sonography, and applied AI
- Excellent public health expertise to assist with commercialization in multiple jurisdictions
- Collectively boasting over 1,200 peer reviewed journals
- Expertise across multiple international markets including the US, Europe, and Asia Pacific
- Multiple key opinion leaders assist with product uptake in hospital groups



Specialist Advisors and Technology Developers:



Prof. David Playford
Advisor



Prof. Geoff Strange
Advisor

Scientific Advisory Board:



Huon H. Gray
CBE MD FRCP FESC
MACC



Madeline Jankowski
BS ACS RDCS
FASE



Jordan B Strom
MD MSc FACC
FASE



Michael J Mack
MD MACC



David Ouyang
MD FACC FASE



James D Thomas
MD FACC FASE
FESC



Hashim A Khan
MD FACC

Corporate Overview


Corporate Snapshot:

Shares on issue:	585.5m
ASX code:	EIQ
OTC code:	ECHQ.F
Share price: As 7 March 2025	A\$0.27
Market capitalization: As at 0.27 per share	A\$156m
Cash at bank: As 31 December 2024	A\$5.35m
R&D Tax Incentive: Received on 12 February 2025	\$1.26m
Debt:	Nil


Board & Management:

Executive Chair	Mr Andrew Grover
CEO	Mr Dustin Haines
Non-Executive Director	Mr Ken Nelson
Non-Executive Director	Mr Steve Formica
Non-Executive Director	Mr Steve Picton
Company Secretary	Ms Jessamyn Lyons

Shareholder breakdown:



■ Board & Top 20 Shareholders
■ Other shareholders



A Defined Mission

To help more people get matched with the right life-saving treatments for cardiovascular disease, which remains the world's leading cause of death.

2m


Help 2m people
into the right
care by 2030



Investment Summary


Strong investment thesis and multiple pending value catalysts:

- Aortic stenosis solution cleared by FDA with defined pathway for EchoSolv HF to gain clearance this year
- Flagship integration of EchoSolv AS with Beth Israel Deaconess Medical Center expected to fast track uptake across other US hospital groups
- Multiple licensing opportunities for EchoSolv technology pending
- Reimbursement codes for EchoSolv AS determined with Category III CPT code anticipated mid-CY25
- Receipt of Category III CPT code to turbocharge revenue opportunities
- Negotiations with major US healthcare organization to commence EchoSolv HF trial well advanced – trial to commence shortly



What we do

EchoiQ harnesses the power of **artificial intelligence** and exclusive access to world leading **cardiac big data** to help healthcare professionals **obtain earlier and more accurate** diagnosis of structural heart disease



Tackling Healthcare's Biggest Problem

Diseases of the heart are the **leading cause of death worldwide**

While treatment options are improving, accurate diagnosis remains complex

Delayed or missed diagnoses cost lives and impact healthcare systems

\$250Bn⁴


US health expenditure on cardiovascular disease

33 sec⁵

One person dies every 33 seconds in the US of CV disease

50%⁶

Missed or under diagnosed for heart failure



⁴Circulation. 2024;149:e347–913.

⁵National Center for Health Statistics. Multiple Cause of Death 2018–2022 on CDC WONDER Database. Accessed May 3, 2024.

⁶PMID: 37702348; PMCID: PMC10682848

Technology Benefits

- ✓ Improved diagnostic accuracy 98.6% vs human only diagnosis 58 - 83%*
- ✓ 20+% reduction in echo reading time
- ✓ Realtime diagnosis - results available in under 3 seconds
- ✓ Consistent diagnosis regardless of age, sex or race
- ✓ Earlier detection of disease
- ✓ Increased valve referrals to Heartcare Team



October 2024





* American Heart Journal Plus: Cardiology Research and Practice 48 (2024) 100485

Total Addressable Market in the US



Heart Failure:

- ~10m echocardiograms per year
- Reimbursement of US\$200 to US\$300 for HF diagnosis
- 6.7m sufferers with 1.2m new diagnoses per year
- Only 50% of all cases are accurately diagnosed



Aortic Stenosis:

- 6m echocardiograms per year
- Reimbursement of US\$100 to US\$150 for AS diagnosis
- 5m heart valve disease sufferers with 1.5m new diagnoses p.a.
- Only 60% accurately diagnosed



⁷Circulation: Cardiovascular Interventions Volume 13, Number 5

⁸U.S. Minimally Invasive Surgical Instruments Market Size, Share & Trends Analysis Report By Device (Handheld Instruments, Inflation Devices), By Application (Cardiac, Gastrointestinal), By End-use, And Segment Forecasts, 2024 - 2030


⁹PMCID: PMC7546989 PMID: 32812149

⁰Cardiovascular Market by Product Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices, etc.), by Application (Coronary Artery Disease, Heart Failure, etc.), by End-user (Hospitals, Specialty Clinics, etc.), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034." (2025). *Market Research Report*. URL (if applicable).


EchoSolv: Rapid Development and Testing

Following algorithm development in 2021, Echo IQ has considerably advanced validation, regulatory, and reimbursement initiatives in EchoSolv for Aortic Stenosis and Heart Failure

Aortic Stenosis:



Heart Failure:



EchoSolv: Clinical Evidence



Beth Israel Deaconess
Medical Center
(Harvard Medical School)

Study Size:
31,141

Key Findings:

1. **EchoSolv** identified **100%** of the patients with guideline-defined severe aortic stenosis, equal to c. 5% of the study population.
2. **EchoSolv** identified an **additional** cohort, similar in size, at high risk of mortality.
3. **3 in 4** of the EchoSolv identified cases with AS had **NOT** received **treatment**.



ST VINCENT'S
HEALTH AUSTRALIA

Study Size:
8,257

Key Findings:

1. **EchoSolv** identified **100%** of the patients with guideline-defined severe aortic stenosis, equal to c. 4% of the study population.
2. **EchoSolv** identified an **additional** cohort, about half the size, at high risk of mortality.
3. **42%** of the cases of guideline-defined severe aortic stenosis detected by EchoSolv had previously been missed or underdiagnosed.

International Cohort Study^a

(Published: **JASE**)

Study Size:
248,646 (US and Australia)

Key Findings:

The distribution of AS severity was similar in both the US and Australian cohorts.

Conclusion:

Despite different healthcare systems, similar patterns of mortality existed, linked to increased severe aortic stenosis.

These data support the need to develop and apply more proactive surveillance strategies in this high - risk population.

•^aPMID: 36208655, PMCID: PMC9822866
• DOI:10.1016/j.jecho.2022.09.020



Baylor Scott & White
HEALTH

Study Size:
200,000

Key Findings:

1. **EchoSolv** identified 100% of the patients with guideline-defined severe aortic stenosis.
2. **EchoSolv** identified 15% more patients than human-only diagnosis.
3. **30%** of all cases that were underdiagnosed by human-only were found to be 'low flow', however model still was able to identify this cohort.


Findings presented at prestigious conferences and journal publications




ESC Congress
2024 London
Onsite & Online, 30 August - 2 September



Significant Progress in the Last 60 Days




US Reimbursement Strategy on Track



Reimbursement will be supported with consultant support to provide: Prior Authorization Letter, Appeal Letter, and Medical Necessity Letter. Post Category III approval, commercial payers will be engaged to negotiate full coverage.

Subscription Model with Reimbursement for Aortic Stenosis


Graduated model based on reimbursement approval rates



Model for demonstration:

Annual Subscription Agreement Fee =

(# of Echocardiograms per annum) x (Avg approval of CPT code) x (Reimbursed value)




Will be reviewed with hospital annually



Agreement will graduate as CPT code changes over time




Agreement will graduate as reimbursed value changes over time



EchoSolv AS: Commercialization Underway

Overview:

- **510(k) clearance awarded** by the US FDA in October 2024
- **Flagship integration secured** with Harvard's Beth Israel Deaconess Medical Center, Boston USA
- Miscellaneous reimbursement code identified for users – providing **US\$100-US\$150 in reimbursement to end users**
- Work towards designated CPT code underway – **Category III CPT code anticipated mid CY-25** application completed with highly experience reimbursement consultancy
- **Solution now deployed in multiple sites** with pipeline of large hospital groups and other organizations ready to convert
- **Partnerships** established with imaging software companies (Studycast, ScImage, EncaptureMD)
- **Contract sales team** trained and in field (Cassling Diagnostics N=40)
- Pilot study underway with large device manufacture
- European discussion for potential distribution agreement underway



EchoSolv AS: Flagship Integration


Flagship deployment in Boston underpins strategy to validate technology in partnership with major hospital networks:

- Beth Israel Deaconess Medical Center (BIDMC or Beth Israel) is a leading US healthcare facility and part of Harvard Medical School
- BIDMC has 743 licensed beds, manages ~38,000 inpatient discharges, almost 50,000 emergency visits and 803,00 outpatients per annum
- The group undertakes **~30,000 echo cardiograms each year**
- Integration follows completion of **successful trial in over 31,000 US Medicare beneficiaries** at Beth Israel
- During the **trial EchoSolv AS identified 98% of patients** that met clinical guidelines for severe AS and **over 1,000 patients who likely had the condition but did not meet guidelines**



2025 Commercial Pathway

Three critical stages to accelerate revenue growth into 2026



Heart Failure: A Significantly Larger Issue

6.5m Americans over 20 have heart failure with another 1.2m new cases found per annum

Heart failure is the **leading cause of re-hospitalization in the US**

Heart failure accounts for **17% of all US healthcare expenditure** and is a **US\$70Bn annual market**

Current clinical practice has an **observed detection rate of 50%**

\$70Bn*


Total cost to the US
Healthcare system
annually

50%⁶

Patients are missed
or underdiagnosed

25%ⁱ

1 in 4 patients in
the US are
readmitted within
30 days



*January 25, 2022 | *Cardiovascular Business* | [Heart Failure](#)

⁶PMID: 37702348; PMCID: PMC10682848

ⁱCirculation, Volume 125, Number 4

Heart Failure detection AI for diagnostic decision support in echocardiography-HFDetect-AI

Professor Geoffrey A. Strange


Professor, School of Medicine University of Notre Dame Australia

Founder, CI and Director NEDA Ltd

Cardiology Dept. Royal Prince Alfred Hospital

....On Behalf of Prof David Playford, Prof Simon Stewart and Dr Andrew Watts

EchoSolv HF: A Solution for a Major Condition




Study Outputs:


50% of patients in this cohort were misdiagnosed or underdiagnosed

AI alone detected **86%** of patients with HF

AI with Cardiologist review detected **97%** of patients with HF




EchoSolv HF: Defined Regulatory Pathway



Advanced negotiations with a **leading US healthcare group** for validation trial underway

The Company expects **510(k) clearance for heart failure within the next 12 months**

Clinical Pipeline



Scalable Business

Integration

Rapid deployment with hospitals, clinics, and partners

Integrate EchoSolv solution into hospital workflow and continue to educate users

Reimbursement

Revenue sharing opportunities

Upon receipt of Category III CPT code and designated CPT Code, enhanced business model opportunities

Pipeline

Provides long term sustainable growth

Utilizing exclusive access to the cardiac echo data base, R&D continues with additional disease areas

Licensing Opportunities

Device Manufacturers

Identify additional patients that would benefit from a valve intervention or alternative treatment route

Pharmaceutical Companies

Identification of additional patients that require drug therapies from major sector participants

Hardware and Service


Remote patient monitoring and Predictive Preventive and Personalized Medicine (PPPM) opportunities



Contact:

Mr Dustin Haines
Chief Executive Officer
Dustin.haines@echoiq.ai
+1 (919) 624 5212

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 (0) 431 271 538





Disclaimer and Forward-looking Statements

This presentation has been prepared by ECHOIQ LIMITED “EIQ”. This document contains background information about EIQ current at the date of this presentation. The presentation is in summary form and does not purport to be all inclusive or complete. Recipients should conduct their own investigations and perform their own analysis in order to satisfy themselves as to the accuracy and completeness of the information, statements and opinions contained in this presentation.

This presentation is for information purposes only. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sales of shares or other financial products in any jurisdiction. The distribution of this presentation outside Australia may be restricted by law. Any recipient of this presentation outside Australia must seek advice on and observe any such restrictions.

This presentation does not constitute investment advice and has been prepared without taking into account the recipient’s investment objectives, financial circumstances or particular needs and the opinions and recommendations in this presentation are not intended to represent recommendations of particular investments to particular persons. Recipients should seek professional advice when deciding if an investment is appropriate. All securities involve risks which include (among others) the risk of adverse or unanticipated market, financial or political developments.

To the fullest extent permitted by law, EIQ, its officers, employees, agents and advisors do not make any representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of any information, statements, opinions, estimates, forecasts or other representations contained in this presentation. No responsibility for any errors or omissions from this presentation arising out of negligence or otherwise are accepted. Images are used to illustrate concepts only and are not intended to represent commercial EIQ images.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions which are outside the control of EIQ. Actual values, results or events may be materially different to those expressed or implied in this presentation. Given these uncertainties, recipients are cautioned not to place reliance on forward looking statements. Any forward-looking statements in this presentation speak only at the date of issue of this presentation. Subject to any continuing obligations under applicable law, EIQ does not undertake any obligation to update or revise any information or any of the forward-looking statements in this presentation or any changes in events, conditions, or circumstances on which any such forward looking statement is based.